Abstract
Antisense long noncoding RNAs (lncRNAs) are reported to play a regulating role in carcinogenesis of various human malignancies. However, the function of lncRNAs and their underlying mechanism in renal cell carcinoma (RCC) is still unknown. The aims of this study are to investigate the expression of lncRNA BX357664 in RCC and to explore its function in RCC cell lines. As a result, BX357664 was downregulated in RCC according to previous microarray analysis and qualitative real-time polymerase chain reaction. After the upregulation of BX357664, reduced migration, invasion, and proliferation capabilities in RCC cells were detected. Furthermore, Western blot analysis was conducted to identify the influence of BX357664 on epithelial-to-mesenchymal transition, matrix metalloproteinase 2, matrix metalloproteinase 9, and transforming growth factor-beta 1 (TGF-β1)/p38/HSP27 signaling pathway in RCC. Subsequently, upregulating the protein level of TGF-β1 in the presence of BX357664 could rescue the suppression of the malignant behavior mediated by BX357664, indicating that BX357664 attributed its inhibitory role to the suppression of TGF-β1. Therefore, we investigated a novel lncRNA BX357664, which might exhibit its inhibitory role in RCC metastasis and progression by blocking the TGF-β1/p38/HSP27 pathway.
Highlights
Renal cell carcinoma (RCC) accounts for 2% to 3% of all malignancies in Western countries and represents approximately 90% of all kidney cancers [1, 2]
Qualitative real-time polymerase chain reaction was conducted to investigate BX357664 expression in 38 paired renal cell carcinoma (RCC) tissues and adjacent normal tissues to validate the deregulation of BX357664 from microarray data(p < 0.01; Figure 1B)
Considering that the inhibitory role of BX357664 in RCC cell migration and invasion had been verified and epithelial-to-mesenchymal transition (EMT) was previously reported to be linked with cancer metastasis, we further investigated whether BX357664 could affect EMT markers in RCC cells
Summary
Renal cell carcinoma (RCC) accounts for 2% to 3% of all malignancies in Western countries and represents approximately 90% of all kidney cancers [1, 2]. Approximately 20% to 40% of patients still develop metastasis or local recurrence after nephrectomy, with a median survival of only 6 months to 12 months and a 5 year survival of 9% [4, 5]. NcRNAs are basically divided into two groups based on their size, namely, small noncoding RNAs and long noncoding RNAs (lncRNAs). Small noncoding RNAs, microRNAs, have been extensively investigated for several decades, and their biological functions in various cancers have been uncovered [8]. The function of lncRNAs in numerous cancers still remains unknown
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
